Traded Mar 15, 2023 · filed 1,080 days later
Compensation award — excluded from discretionary-purchase analysis.
Traded Jan 20, 2026 · Filed Jan 29, 2026
United Therapeutics's PRESIDENT AND COO sold $1.06M of United Therapeutics shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$1,055,264
Shares × reported transaction price
83 days after results of Oct 29, 2025, 36 days before results of Feb 25, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +2.4% | −2.4% | +4.8% |
| 30 days | +9.9% | −1.1% | +11.0% |
| 90 days | +22.1% | +2.5% | +19.6% |
| 180 days | +12.0% | +6.8% | +5.2% |
Past results only. Not a forecast.
Traded Mar 15, 2023 · filed 1,080 days later
Compensation award — excluded from discretionary-purchase analysis.
Traded Mar 15, 2023 · filed 1,080 days later
Compensation award — excluded from discretionary-purchase analysis.
Traded Mar 15, 2023 · filed 1,080 days later
Compensation award — excluded from discretionary-purchase analysis.